Loading clinical trials...

COMPLETED

Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy

An Evaluation of Lung Function and Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy

NCT00791518•GlaxoSmithKline

View on ClinicalTrials.gov

Summary

A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.

Eligibility

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Cigarette smoking history-Current or ex-smokers (defined as stopped smoking for at least three months prior to the study visit)
•Established history of COPD as diagnosed by a physician
•Regular use (prescribed for use every day) of only one long-acting bronchodilator greater than or equal to one month before the study visit
•Ability to read, comprehend, and record information in the English language

Exclusion Criteria

•Currently active asthma (receiving asthma therapy and or having asthma symptoms)
•Use of ipratropium/albuterol combination products greater than three times per day, use of inhaled corticosteroids, use of inhaled corticosteroid/long-acting beta-agonist combinations, theophylline preparations, or oral beta agonists within 3 months prior to the study visit
•Previous lung surgery
•Other respiratory disorders other than COPD
•Current alcohol, illegal drug, or solvent abuse
•Females with a positive urine pregnancy test at the study visit

Locations (57)

GSK Investigational Site

Birmingham, Alabama, United States

GSK Investigational Site

Tucson, Arizona, United States

GSK Investigational Site

Little Rock, Arkansas, United States

GSK Investigational Site

National City, California, United States

GSK Investigational Site

Rancho Mirage, California, United States

GSK Investigational Site

Riverside, California, United States

GSK Investigational Site

Santa Ana, California, United States

GSK Investigational Site

Walnut Creek, California, United States

GSK Investigational Site

Colorado Springs, Colorado, United States

GSK Investigational Site

Colorado Springs, Colorado, United States

Key Dates

Start Date

December 1, 2008

Primary Completion Date

May 1, 2009

Completion Date

May 1, 2009

Last Updated

July 30, 2014

Enrollment

1,084

ACTUAL participants

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

No intervention

DRUG

Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity

NCT06831994

Asthma BronchialeBreast Neoplasms+11 more

View study

RECRUITING

The London COPD Exacerbation Cohort

NCT02755974

Pulmonary Disease, Chronic Obstructive

View study

ACTIVE_NOT_RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 30, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy

Inclusion Criteria

Exclusion Criteria

Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity

The London COPD Exacerbation Cohort

Evaluating the Clinical Effectiveness of a Patient-specific Silicone Stent

Air Filtration for COPD in VA Population of Veterans

A Study of the Effect of a Nurse Navigator Program on High Risk Patients

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)